Japanese team from Osaka University found that Delta-variant escaped neutralizing antibodies, was more responsive to infectivity-enhancing antibodies.
Incidentally, Japanese researchers (not this team) were the ones that discovered mRNA lipid nanoparticles left the injection site and traveled to distant organs including the liver, the spleen, the adrenals, the ovaries, and others.